NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Complementing Tumor Tissue Profiling with Plasma-based Global Resolution NeXT Liquid Biopsy™, a high-performance, exome-wide liquid biopsy assay, is designed to complement Personalis’ flagship tissue-based immunogenomics platform, ImmunoID NeXT™, to further enhance the development of [...]
Dr. Lyle joined Personalis in 2020 to manage the company’s assay research and development efforts. Prior to assuming this role, he spent 14 years at Pacific Biosciences where he most recently served as Senior Director of Single Molecule Sequencing focusing on reagent, system, and application development of long-read, ultra-high accuracy sequencing. Dr. Lyle received his [...]
Dr. Leslie Grab joined Personalis in June 2020 to lead the company's intellectual property efforts. Dr. Grab has over a decade of experience working with genomic testing, diagnostics, and biotechnology. Prior to joining Personalis, she worked at Verily Life Sciences (a Google spin-out) and at the law firm of Kilpatrick Townsend & Stockton. Dr. Grab [...]
2020 AACR: Enhanced Whole Exome Profiling of Tumor Circulating Cell-Free DNA Enables Sensitive Assessment of Tumor Mutations An increasing number of studies have demonstrated the potential use of circulating cell-free DNA (cfDNA) for diagnosis, prognosis, and disease progression monitoring. However, many of these studies utilize assays covering a limited set of well known genes, [...]
2020 AACR: Improved Tumor-Only Somatic Variant Calling Using a Gradient Boosted Machine Learning Algorithm Accurate identification of somatic variants in a tumor sample is often accomplished by utilizing a paired normal tissue sample from the same patient to enable the separation of private germline mutations from somatic variants. However, a paired normal sample is [...]
2020 AACR: A diagnostic platform for precision cancer therapy enabling composite biomarkers by combining tumor and immune features from an enhanced exome and transcriptome While the success of immune checkpoint blockade (ICB) has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies requires a more comprehensive approach to tumor immunogenomic profiling. There [...]
2020 AACR: A Pan-Cancer Characterization of Both the Tumor and Micro Environment Highlights the Importance of an Integrated Approach for Immuno-Oncology A better understanding of the characteristics of cancer across different indications is required to drive the development of personalized treatments, inform therapy decisions, and improve outcomes. Integrating data from the tumor and the [...]
2020 AACR: Composite neoantigen score is more strongly associated with therapeutic response than tumor mutational burden in a cohort of late-stage anti-PD-1-treated melanoma patients Checkpoint inhibitor therapy has demonstrated meaningful, if varied, antitumor activity, with patient response influenced by a variety of biological factors, including complex interactions between the tumor and immune system. Thus, [...]
2020 AACR: Quantification of tumor-infiltrating immune cell populations with an augmented transcriptome Comprehensive characterization of the tumor and tumor microenvironment (TME) can improve our understanding of tumor progression and treatment outcomes. In particular, quantification of the immune infiltrate has the potential to inform mechanisms of immune escape and predict response to therapy. Standard experimental [...]
2020 AACR: Precision neoantigen discovery using a pan-predictive machine learning model integrated into ImmunoID NeXT Platform® Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Our ImmunoID [...]
